PRECLINICAL AND CLINICAL STUDIES OF CLINDAMYCIN-2-PHOSPHATE

Preclinical and clinical studies of clindamycin-2-phosphate developed as an injectable were conducted, and the following results were obtained: 1) Clindamycin-2-phosphate administered by the intravenous drip in a dose of 600mg over one hour showed a peak blood clindamycin level of 10.5mcg/ml at the...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1977/01/25, Vol.30(1), pp.42-50
Main Authors: SAWAE, YOSHIO, TAKII, MASAHIDE
Format: Article
Language:Japanese
Subjects:
Adult
Aged
Clindamycin - analogs & derivatives
Clindamycin - metabolism
Clindamycin - therapeutic use
Female
Humans
Infusions, Parenteral
Injections, Intramuscular
Male
Middle Aged
Middle Lobe Syndrome - drug therapy
Organophosphorus Compounds
Pneumonia - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preclinical and clinical studies of clindamycin-2-phosphate developed as an injectable were conducted, and the following results were obtained: 1) Clindamycin-2-phosphate administered by the intravenous drip in a dose of 600mg over one hour showed a peak blood clindamycin level of 10.5mcg/ml at the end of administration. Though the blood level then decreased rapidly, it stayed at 0.7mcg/ml at 8 hours later. 2) The blood level of clindamycin following intramuscular injection of 300mg of clindamycin-2-phosphate reached a peak of 3.3mcg/ml at one hour later. The blood level at 6 hours after injection was 1.0mcg/ml. 3) Clindamycin-2-phosphate 300mg was given intramuscularly 2 to 4 times daily for 5-14 days in 4 cases of pneumonia. The drug proved effective in two cases of pneumonia due to Mycoplasma; fairly effective in another case of mixed infection caused by pneumococci, Hemophilus and N. meningitidis; and ineffective in the fourth case of infection due to Hemophilusp arainfluenzae.4) No such adverse reactions as hepatic disorder, renal disorder and colitis were noted following administration of clindamycin-2-phosphate.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.30.42